Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo‐controlled, double‐blind 2‐week study
Open Access
- 10 December 2012
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (3), 346-354
- https://doi.org/10.1111/apt.12174
Abstract
Background Although nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely prescribed globally, their chronic use increases the risk of upper gastrointestinal (GI) damage. Cyclooxygenase‐2–selective NSAIDs are considered to reduce this risk. Current guidelines in Japan recommend loxoprofen sodium (loxoprofen), a pro‐drug in the propionic acid class of nonselective NSAIDs, as first‐line therapy in rheumatoid arthritis. Aim To confirm the superiority of celecoxib, a cyclooxygenase‐2‐selective NSAID, to loxoprofen in the incidence of gastroduodenal (GD) endoscopic ulcers. Methods A randomised, multicentre, placebo‐controlled, double‐blind, phase IV clinical trial in healthy Japanese volunteers [mean age 57.5 (range: 40–74) years; >70% female], stratified by Helicobacter pylori status at screening (∼40% positive) and randomised 2:2:1 to receive celecoxib 100 mg b.d., loxoprofen 60 mg t.d.s. or placebo. Primary end point was incidence of any GD endoscopic ulcers after 2 weeks of treatment. Results Of 190 randomised subjects, 189 received at least one dose of celecoxib (n = 76), loxoprofen (n = 76), or placebo (n = 37). Incidence of GD ulcers was 1.4%, 27.6% and 2.7% in the celecoxib, loxoprofen and placebo groups respectively (P < 0.0001 in favour of the celecoxib group); incidence of adverse events (AEs) was 34.2%, 51.3% and 21.6% in the celecoxib, loxoprofen and placebo groups respectively. No serious or severe AEs were reported. Conclusions Celecoxib 100 mg b.d. was superior to loxoprofen 60 mg t.d.s. regarding the incidence of gastro‐duodenal endoscopic ulcers over 2 weeks. Celecoxib was well tolerated and no major safety concerns were observed. ClinicalTrials.gov NCT00994461.Keywords
This publication has 26 references indexed in Scilit:
- Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse eventsClinical Therapeutics, 2010
- Nonsteroidal Anti-Inflammatory Drugs and Lower Gastrointestinal ComplicationsGastroenterology Clinics of North America, 2009
- A Questionnaire-Based Survey on the Prescription of Non-Steroidal Anti-Inflammatory Drugs by Physicians in East Asian Countries in 2007Digestion, 2009
- Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysisJournal of Orthopaedic Science, 2007
- Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in JapanInternal Medicine, 2007
- Differential Inhibition of Cyclooxygenase Isoforms An Explanation of the Action of NSAIDsJCR: Journal of Clinical Rheumatology, 1998
- Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Renal complications of nonsteroidal anti-inflammatory drugsKidney International, 1993
- Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1992